Nasal vaccines, or more accurately known as intranasal vaccines, can protect against airborne pathogens that enter through the nose causing the flu or the coronavirus. Research shows that delivering the vaccine directly to the mucosa might be a better approach for preventing Covid infection.
Mayuresh Abhyankar, a researcher at the University of Virginia, studies infectious diseases and works on intranasal vaccines. He explains that vaccinating someone right where the coronavirus is likely to start its attack comes with many immunological benefits. As of May 2022, there are no approved COVID-19 intranasal vaccines for human use. However, there are currently seven in clinical trials at Beijing Wantai Biological Pharmacy, and India’s Bharat Biotech. New York-based Codagenix has established a development and manufacturing partnership with Pune, India-based Serum Institute of India, the world’s largest vaccine manufacturer by doses produced and sold.
In late May 2022, Codagenix initiated a Phase 1 Evaluation of Intranasal Vaccine CoviLiv™ for use as a COVID-19 booster in collaboration with Serum Institute of India.
